{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:41:08Z","timestamp":1760060468403,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: To compare the costs of open retropubic radical prostatectomy (RRP), robotic-assisted radical prostatectomy (RALP), intensity-modulated radiation therapy (IMRT), low-dose brachytherapy (LDBT), stereotactic body radiotherapy (SBRT), cryotherapy (Cryo), and high-intensity focused ultrasound (HIFU) for low\/intermediate-risk prostate cancer (PCa), from the healthcare system perspective. Methods: This retrospective, IRB-approved study compared the costs and charges of primary treatment options for localized PCa at Duke University Hospital between January 2018 and December 2019. We identified cases by querying the relevant disease, procedural, and charge codes from Duke Finance. Consecutive cases with NCCN high-risk disease, prior treatment, or missing institutional financial information were excluded. Costs were calculated from the point at which the treatment option was selected until the last treatment session (SBRT and IMRT) or hospital discharge (other modalities). All modalities except RRP were considered technology-intensive. Results: A total of 552 patients with a mean age of 65.0 years met the inclusion criteria. NCCN risk categories included 85 (13%) low, 218 (41%) favorable-intermediate, and 249 (46%) unfavorable-intermediate risk cases. RALP, RRP, Cryo, and HIFU were single-session treatments, whereas IMRT, SBRT, and LDBT were delivered over multiple sessions. IMRT and SBRT were the most expensive modalities, followed by RALP, HIFU, LDBT, Cryo, and RRP. The number of sessions (\u03c1 = 0.55, p &lt; 0.001) and being technology-intensive (\u03c1 = 0.58, p &lt; 0.001) were significantly correlated with treatment costs. Conclusions: In this cohort of PCa patients, treatment costs were highest for IMRT and SBRT, followed by RALP, HIFU, LDBT, Cryo, and RRP. The number of treatment sessions was a significant predictor of higher costs.<\/jats:p>","DOI":"10.3390\/cancers17172814","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:29:18Z","timestamp":1756376958000},"page":"2814","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Economic Evaluation of Radical Prostatectomy, Radiation, and Ablative Techniques in the Management of Localized Prostate Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-5658","authenticated-orcid":false,"given":"Mahdi","family":"Mottaghi","sequence":"first","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"},{"name":"Durham Veteran Affairs Health System, Institute for Medical Research, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-7240","authenticated-orcid":false,"given":"Alireza","family":"Ghoreifi","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriram","family":"Deivasigamani","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"},{"name":"Durham Veteran Affairs Health System, Institute for Medical Research, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8919-2042","authenticated-orcid":false,"given":"Sudharshanan","family":"Balaji","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5512-2404","authenticated-orcid":false,"given":"Michael C.","family":"Ivey","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cary N.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"},{"name":"Durham Veteran Affairs Health System, Institute for Medical Research, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-8344","authenticated-orcid":false,"given":"Judd W.","family":"Moul","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-2924","authenticated-orcid":false,"given":"Ryan E.","family":"Fecteau","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Centre, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Polascik","sequence":"additional","affiliation":[{"name":"Department of Urology, Duke University Medical Centre, Durham, NC 27710, USA"},{"name":"Durham Veteran Affairs Health System, Institute for Medical Research, Durham, NC 27710, USA"},{"name":"Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA"},{"name":"Duke Cancer Institute, Duke University Medical Centre, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref_1","unstructured":"AmericanCancerSociety (2025, May 20). Initial Treatment of Prostate Cancer, by Stage and Risk Group. Available online: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/treating\/by-stage.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41391-023-00702-1","article-title":"The state of focal therapy in the treatment of prostate cancer: The university of California collaborative (UC-Squared) consensus statement","volume":"27","author":"Brisbane","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_5","unstructured":"Eltorai, A.E.M., Arab, A., Atala, A., and Siddiqui, M.M. (2025). Chapter 85\u2014Building a team and implementing a urology care initiative. Translational Urology, Academic Press."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nasseri, P., Veldwijk, J., Niehot, C., Mulder, E.F.H., de Bekker-Grob, E.W., Roobol, M.J., and Venderbos, L.D.F. (2025). Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review. J. Pers. Med., 15.","DOI":"10.3390\/jpm15070315"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.aju.2018.06.008","article-title":"Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer","volume":"16","author":"Nazim","year":"2018","journal-title":"Arab J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cncr.30423","article-title":"A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment","volume":"123","author":"Shih","year":"2017","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cantarero-Prieto, D., Lera, J., Lanza-Leon, P., Barreda-Gutierrez, M., Guillem-Porta, V., Castelo-Branco, L., and Martin-Moreno, J.M. (2022). The Economic Burden of Localized Prostate Cancer and Insights Derived from Cost-Effectiveness Studies of the Different Treatments. Cancers, 14.","DOI":"10.3390\/cancers14174088"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/13696998.2023.2251849","article-title":"Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: Results of a cost-effectiveness analysis","volume":"26","author":"Reddy","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e088495","DOI":"10.1136\/bmjopen-2024-088495","article-title":"Cost-utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer","volume":"15","author":"Muhler","year":"2025","journal-title":"BMJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamaoncol.2019.5690","article-title":"Analysis of Price Transparency via National Cancer Institute-Designated Cancer Centers\u2019 Chargemasters for Prostate Cancer Radiation Therapy","volume":"6","author":"Agarwal","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"Griffin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.prro.2020.02.014","article-title":"Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data","volume":"10","author":"Tang","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e212265","DOI":"10.1001\/jamanetworkopen.2021.2265","article-title":"Comparison of 1-Year Health Care Costs and Use Associated With Open vs Robotic-Assisted Radical Prostatectomy","volume":"4","author":"Okhawere","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2025.01.011","article-title":"Economic Evaluation of Robotic-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis","volume":"72","author":"Bejrananda","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41391-022-00608-4","article-title":"The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer","volume":"26","author":"Posielski","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Deivasigamani, S., Kotamarti, S., Mottaghi, M., Ghoreifi, A., and Polascik, T.J. Long-term Oncological Outcomes of Partial Gland Cryoablation of Localized Prostate Cancer with Median Follow-up of 7 Years: A Single-institution Experience. Eur. Urol. Focus, 2025. in press.","DOI":"10.1016\/j.euf.2025.01.004"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41391-023-00715-w","article-title":"Quality: A parallel priority to quantity in prostate cancer focal therapy","volume":"27","author":"Mottaghi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2023.06.013","article-title":"Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement","volume":"84","author":"Deivasigamani","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Marra, G., Marquis, A., Suberville, M., Woo, H., Govorov, A., Hernandez-Porras, A., Bhatti, K., Turkbey, B., Katz, A.E., and Polascik, T.J. (2024). Surveillance after Focal Therapy\u2014A Comprehensive Review. Prostate Cancer Prostatic Dis., 1\u201310.","DOI":"10.1038\/s41391-024-00905-0"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23814683241282413","DOI":"10.1177\/23814683241282413","article-title":"\u201cI Just Had to Do What I Had to Do\u201d: Characterizing Direct and Indirect Prostate Cancer Treatment Costs for Black Survivors and Their Caregivers","volume":"9","author":"Rice","year":"2024","journal-title":"MDM Policy Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pros.24434","article-title":"Prostate cancer aggressiveness and financial toxicity among prostate cancer patients","volume":"83","author":"Kc","year":"2023","journal-title":"Prostate"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.5489\/cuaj.8228","article-title":"A prospective evaluation of patient perspectives and financial considerations during prostate cancer treatment decision-making","volume":"17","author":"Rai","year":"2023","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.euo.2024.04.016","article-title":"Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review","volume":"7","author":"Gartrell","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_27","first-page":"94","article-title":"Beyond Medical Bills: The Indirect Costs of Prostate Cancer","volume":"12","author":"Michel","year":"2025","journal-title":"Urol. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41585-019-0258-3","article-title":"Financial toxicity associated with treatment of localized prostate cancer","volume":"17","author":"Imber","year":"2020","journal-title":"Nat. Rev. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2814\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:24Z","timestamp":1760034864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":29,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172814"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172814","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}